Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

Agree...Excellent review:

Thanks for posting, Farrell

Brilacidin COVID-19 Antiviral News

March 2, 2021 - Innovation Pharmaceuticals announced the publication of a peer-reviewed scientific article—Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture—in the journal Viruses. Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals, commented, “Infectious disease experts have noted the next phase in the global fight against COVID-19 will be in developing potent antivirals that directly act on the SARS-CoV-2 virus—which is what Brilacidin has been shown to do in pre-clinical studies.

February 26, 2021 - Innovation Pharmaceuticals provided additional study details for its ongoing Phase 2 clinical trial assessing Brilacidin as a novel therapeutic in hospitalized patients with COVID-19. Patients are being treated, with recruitment and enrollment progressing at trial sites.

January 14, 2021 - Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation. Laboratory testing at independent laboratories supports Brilacidin’s antiviral ability to safely and potently inhibit SARS-CoV-2 and multiple strains of human coronaviruses. In a human lung cell line against SARS-CoV-2, Brilacidin achieved a Selectivity Index of 426. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Brilacidin antiviral research to date has been limited to laboratory-based experiments.

December 21, 2020 - The U.S. FDA Granted IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19. Brilacidin’s potent in vitro inhibition of the Washington and Italian strains of SARS-CoV-2 supports its potential to inhibit emerging coronavirus mutations (variants), such as those in the United Kingdom, Denmark, and South Africa.

November 30, 2020 - Innovation Pharmaceuticals COVID-19 Clinical Trial to Support Additional Development of Brilacidin as a “Pan-Coronavirus” Therapeutic. Additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin mimetic, can treat other endemic human coronaviruses (H-CoVs), such as those causing common colds, and not just SARS-CoV-2, the novel coronavirus responsible for the ongoing global COVID-19 pandemic.

November 16, 2020 - Innovation Pharmaceuticals announced that an overseas Clinical Trial Application (CTA) had been submitted to the governing health agency, with a U.S. Investigational New Drug (IND) application also to be submitted this week to the FDA. Both these submissions are part of final preparations for the Company’s multinational Phase 2 clinical trial of Brilacidin for COVID-19, which is on track to commence in 2020 upon gaining required approvals.

October 30, 2020 - Innovation Pharmaceuticals and George Mason University’s (Mason’s) National Center for Biodefense and Infectious Diseases (NCBID) jointly announced the completion of extensive laboratory testing supporting the anti-SARS-CoV-2 activity of Brilacidin, a defensin-mimetic drug candidate, which is being developed as a potential COVID-19 treatment. “In testing at GMU’s BSL-3 lab, we showed that Brilacidin potently inhibits SARS-CoV-2 in vitro against the live virus. Beyond exhibiting treatment potential for those already infected by COVID-19, Brilacidin’s ability to disrupt viral integrity and block viral entry indicates it has the added potential to prevent infection, upon appropriate formulation, as a prophylactic. I look forward to working with Innovation to investigate further Brilacidin’s antiviral properties,” said Aarthi Narayanan, Ph.D., Associate Professor of Systems Biology in Mason’s College of Science.
Brilacidin COVID-19 Antiviral Clinical Trial

The Phase 2 clinical trial will be a randomized, double-blind, placebo-controlled, multi-national, multi-center study that is expected to enroll approximately 120 patients with moderate-to-severe COVID-19. The trial’s primary endpoint is time to sustained recovery through Day 29 based on the National Institute of Allergy and Infectious Diseases Adaptive COVID-19 Treatment Trial clinical status ordinal scale.
Related Articles
reserach lab

Fact checked by Robert Carlson, MD
3 in 1 Combination COVID-19 Therapeutic Launches Late-Stage Study
Innovation Pharmaceuticals Brilacidin is a combination antiviral, immuno/anti-inflammatory, and antimicrobial COVID-19 therapeutic candidate

https://www.precisionvaccinations.com/vaccines/brilacidin-covid-19-therapeutic
Vaccine Data
Condition:
COVID-19
Drug Class:
Antiviral
Name
Brand:
Brilacidin
Generic:
PMX-30063
Manufacturer
Innovation Pharmaceuticals Inc
Country ID:
US
Code
ChEMBL ID:
25023695
Accession Number:
DB12997
UNII:
I1679X069H
Status
Status:
Candidate
FDA First In Class:
Yes
Availability:
Pending
Clinical Trials
Clinical Trial Phase II:
Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer (Brilaci
External Data
VIS:
PDF
New Vax Data
VIR-7831 Antibody
Janssen COVID-19 Vaccine (Ad26.COV2-S)
Herpes Vaccine Candidates
Plaquenil Antiviral Medication
Pfizer-BioNTech COVID-19 Vaccine
Moderna COVID-19 Vaccine
Sputnik V Vaccine
Sci-B-Vac Hepatitis B Vaccine
Brilacidin COVID-19 Therapeutic
VBI-1901 Glioblastoma (GBM) Cancer Vaccine
VBI-2601 Hepatitis B Vaccine
VGX-3100 HPV Cancer Vaccine